Header Logo

Connection

Sonal Singh to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications Sonal Singh has written about Hypoglycemic Agents.
Sonal Singh
Connection Strength
4.067
Hypoglycemic Agents
  1. Singh S, Wright EE, Kwan AY, Thompson JC, Syed IA, Korol EE, Waser NA, Yu MB, Juneja R. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017 02; 19(2):228-238.
    View in: PubMed
    Score: 0.520
  2. Singh S, Suchard MA. Pioglitazone Use and Risk of Bladder Cancer. JAMA. 2015 Dec 15; 314(23):2567-8.
    View in: PubMed
    Score: 0.486
  3. Maruthur NM, Joy SM, Dolan JG, Shihab HM, Singh S. Use of the analytic hierarchy process for medication decision-making in type 2 diabetes. PLoS One. 2015; 10(5):e0126625.
    View in: PubMed
    Score: 0.467
  4. Singh S. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy. Curr Diab Rep. 2014 Dec; 14(12):563.
    View in: PubMed
    Score: 0.452
  5. Singh S, Segal JB. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Arch Intern Med. 2012 Jul 09; 172(13):1011-3.
    View in: PubMed
    Score: 0.383
  6. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011 Mar 17; 342:d1309.
    View in: PubMed
    Score: 0.350
  7. Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. Thorax. 2011 May; 66(5):383-8.
    View in: PubMed
    Score: 0.348
  8. Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2008 Sep; 7(5):579-85.
    View in: PubMed
    Score: 0.293
  9. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12; 298(10):1189-95.
    View in: PubMed
    Score: 0.274
  10. Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):567-75.
    View in: PubMed
    Score: 0.116
  11. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014 Apr; 37(4):985-92.
    View in: PubMed
    Score: 0.105
  12. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011 May 03; 154(9):602-13.
    View in: PubMed
    Score: 0.087
  13. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 06; 180(1):32-9.
    View in: PubMed
    Score: 0.075
  14. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007 Aug; 30(8):2148-53.
    View in: PubMed
    Score: 0.067
  15. Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, Tung YC. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021 03 26; 11(1):7000.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.